Analysts expect Sun to continue to be more aggressive in chasing speciality assets, but a successful launch is necessary for ...

Sun Pharmaceutical Industries—controlled by Indian billionaire Dilip Shanghvi—has agreed to buy U.S.-based immunotherapy and ...

Three months after an FDA approval for cancer immunotherapy Unloxcyt, Checkpoint Therapeutics has found a buyer. | Three ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

India's Sun Pharmaceutical Industries said on Monday it will acquire Checkpoint Therapeutics, a U.S.-based immunotherapy and ...

Sun Pharmaceutical Industries Ltd. closed 14.48% below its 52-week high of 1,960.20 rupees, which the company reached on ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn ...

The country's top specialty generics company recently acquired US-based Checkpoint that will further its oncology portfolio ...

Indian pharma companies are expanding in the US through acquisitions to navigate regulations, diversify portfolios, and ...

Sun Pharmaceutical has agreed to acquire Checkpoint Therapeutics for an aggregate consideration of up to $355m upfront.

The NJEDA Board approved tax credits under the Emerge Program to support Sun Pharmaceutical Industries Inc.’s plan to open a new ...

Sun Pharmaceutical Industries Ltd. closed 14.10% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.